Exploring Considerations In Demonstrating Complex Api Sameness 7of39 Complex Generics 2018
Let's dive into the details surrounding Considerations In Demonstrating Complex Api Sameness 7of39 Complex Generics 2018.
- Bin Qin from CDER's Office of
- Jane Chang from CDER's Office of Pharmaceutical Quality discusses
- Sam Raney, CDER Office of
- Priyanka Ghosh, CDER Office of
- Satish Sharan from CDER's Office of
In-Depth Information on Considerations In Demonstrating Complex Api Sameness 7of39 Complex Generics 2018
Deyi Zhang from CDER's Office of Deyi Zhang from the Office of Research and Standards in the Office of FDA discusses regulatory strategies to show Bin Qin from the Division of Therapeutic Performance in the Office of
Kelley Burridge, CDER Office of Pharmaceutical Quality (OPQ), discusses OPQ
That wraps up our extensive overview of Considerations In Demonstrating Complex Api Sameness 7of39 Complex Generics 2018.